Invited Editorial Focus

The Ultimate Murine Model of Immune Thrombocytopenia

John W. Semple1  Rick Kapur2

1 Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
2 Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands


Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by platelet counts below $100 \times 10^9$/L. Symptoms can manifest as petechiae, purpura, epistaxis, mucosal bleeding and, in rare cases, intracranial haemorrhage all of which lead to a significant reduction in the quality of life. Clinical approaches are complicated by the fact that patients with identical platelet counts can present with different clinical bleeding scenarios. In primary ITP, there is an isolated thrombocytopenia, while in secondary ITP, the thrombocytopenia is related to other autoimmune diseases (e.g. systemic lupus erythematosus) or other conditions such as chronic infections (e.g. Helicobacter pylori). The pathophysiology of ITP is complex and heterogeneous with an important role for anti-platelet autoantibodies and/or T cell-mediated platelet destruction.

To obtain insights into the complex nature of the pathophysiology, multiple murine models of ITP have been developed over the years. Generally, these include the passive ITP model, models of secondary ITP and a model of active ITP. The passive ITP model is based on injection of anti-platelet antibodies however, the thrombocytopenia induced is not suitable to study chronic ITP and repeated anti-platelet injections are required to maintain a durable thrombocytopenia. Moreover, the passive model is not appropriate for studying effector mechanisms related to T cell-mediated platelet destruction. Models of secondary ITP are complicated by the involvement of additional confounding autoimmune factors, and thus, are not ideal to study chronic ITP. In 2010, Chow et al introduced a murine model of active ITP that, for the first time, provided a tool which allowed in-depth investigations into the pathophysiology of chronic ITP. This model has greatly influenced the field as it accurately represents many of the immunopathogenic features of chronic ITP and has a strong resemblance to clinical features of human severe ITP. The model is based on the transfer of splenocytes from mice immune against platelet CD61 into mice with severe combined immunodeficiency (SCID). Importantly, the thrombocytopenia that developed in these mice was induced by effector mechanisms primarily mediated by both anti-platelet antibodies as well as on CD8+ T cells. Of interest, treatment of the SCID ITP mice with intravenous immunoglobulins (IVIgs) increased platelet counts and prevented bleeding mortality induced by antibody-mediated effector mechanisms but not by the T cell-mediated indicating a differential response to IVIg therapy.

In this issue of Thrombosis and Haemostasis, Li et al further illustrate the importance of the active ITP model by changing the antigenic system and immunizing CD41-knockout (KO) mice with platelets of wild-type mice and subsequently transferring these splenocytes into SCID mice. An advantage of using CD41-KO mice instead of the CD61-KO mice is that CD41 is a megakaryocyte- and platelet-specific marker, whereas CD61 is not only expressed by platelets but also present on other cells including endothelial cells. Additionally, placental defects have been described in CD61-KO females with an occurrence of post-natal haemorrhage. Indeed, Li et al demonstrated that loss of CD41 did not affect the survival of embryos or pups. More importantly, they have convincingly validated this new model by assessing platelet counts, antibody levels in serum and bone marrow megakaryocyte numbers in the SCID ITP mice. The SCID mice that received splenocytes from immunized CD41-KO mice suffered from thrombocytopenia that persisted until day 21 and from haemorrhage in the intestines, lungs, brain and abdomen. Together with the thrombocytopenia, increased serum anti-platelet antibodies were also detected which were likely responsible for the platelet destruction. Furthermore, reduced numbers of mature megakaryocytes were observed in the bone marrow of the SCID ITP mice which likely reduced platelet production as seen in human ITP. In addition, when the immune splenocytes were first depleted of CD19+ B cells
before transfer, the SCID mice developed severe thrombocytopenia indicating the occurrence of T cell-mediated platelet destruction. Alternatively, when the transferred splenocytes were first depleted of CD8+ T cells, the number of mature megakaryocytes in the bone marrow significantly increased, indicating that CD8+ T cells may be impairing bone marrow megakaryocyte maturation. Since antibody-mediated platelet destruction in ITP is presumed to occur through phagocytosis in the spleen, the authors then examined the contribution of the spleen in the model. Compared with non-splenectomized SCID mice, transfer of immunized splenocytes into splenectomized mice showed a significant recovery of platelet counts by day 21 in combination with a reduction of anti-CD41 antibody levels. This suggests that the spleen is the major site of both anti-platelet antibody production and platelet destruction in murine ITP.

In summary, Li et al confirm the importance of the murine model of active ITP7 by using a different platelet antigenic system.17 This new model is platelet-specific and demonstrates both antibody- as well as T cell-mediated platelet destruction making it a new valuable tool for in-depth investigations into the pathophysiology of chronic ITP.

Conflict of Interest
None declared.

References